Conclusion: Targeting NLRP3 inflammasome pathway holds promise as a therapeutic approach to counteract pro-tumorigenic inflammation and develop novel treatments for NSCLC. This evidence concerns the gene NLRP3 and non-small cell lung carcinoma.